Category
Molecular Genetic Pathology & Cytogenetics
Sub Category
Oncology (Hematologic Malignancies)
Synonym/Aliases
JAK2 QUALITATIVE; JAK 2 EXON 14
Abbreviations
JAK 2
Type
Individual Test
Results
RESULTS READY WITHIN 14 DAYS
Method
REAL TIME PCR
Temp
ROOM TEMPERATURE REFRIGERATE (2-8ºC).
Setup
BATCHED
Components Parameters
- N/A
PRE-ANALYTIC CONSIDERATIONS
Test Ordering Instructions
FILL OUT TEST REQUEST FORM FULLY & LEGIBLY. CLINICAL HISTORY REQUIRED INCLUDING COMPLETE BLOOD COUNT & BONE MARROW REPORT.
Patient preparation
IN CASE OF SELF SAMPLING, MANUFACTURER'S INSTRUCTIONS FOR SELF COLLECTED SPECIMENS APPLY.
Sample type
WHOLE BLOOD OR BONE MARROW IN EDTA.
Container/ preservative
EDTA (PURPLE TOP) VACUTAINER
Sample volume
3 ML
Rejection criteria
LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE; CLOTTED SAMPLE, HEMOLYZED SAMPLE
Other Instructions
- N/A
Reference intervals
NEGATIVE/ NOT DETECTED. IN CASE OF A NEGATIVE RESULT WITH A HIGH INDEX OF SUSPICION FOR POLYCYTHEMIA VERA, FOLLOW-UP TESTING FOR JAK2 EXON 12 TESTING SHOULD BE DONE.
Clinical Utility
DIAGNOSIS OF MYELOPROLIFERATIVE NEOPLASMS (MPN) E.G. POLYCYTHEMIA VERA, ESSENTIAL THROMBOCYTHEMIA.
Test Limitations/ Confounders
PRESENCE OF PCR INHIBITORS IN THE SAMPLE MAY PREVENT NUCLEIC ACID AMPLIFICATION. PARADOXICAL RESULTS MAY ARISE DUE TO SELECTION OF INAPPROPRIATE SPECIMEN AND CONTAMINATION DURING SPECIMEN COLLECTION.